GLYCOSAMINOGLYCANS HAVING AN AVERAGE MOLECULAR WEIGHT EQUAL TO 2400 D SUITABLE FOR THE TREATMENT OF SENILE DEMENTIA

摘要

The present invention relates to the use of glycosaminoglycans having an average molecular weight equal to 2,400 D for the preparation of pharmaceutical compositions suitable for the treatmet of senile dementia, in particular for the treatmet of Alzheimer's disease or SDAT (Senile Dementia Alzheimer's Type) and of the cerebral neurological lesions from ictus and from traumas.